Abstract Library

#3840 Sneak peek into neuroendocrine tumors (preliminary study) – Reconsideration of histopathological approach and classification

Introduction: Tumorlets and DIPNECH are rare entities often associated with bronchial neuroendocrine tumors and little is known regarding their clinical course and management. However, they are not uncommon findings on CT or MR imaging of patients with known bronchial NENs.

Conference:

Presenting Author:

Authors: Vamvakaris I, Evangelou G, Riga D, Jensen L, Psichoyou E,

Keywords: TUMORLETS, DIPNECH, TYPICAL CARCINOID, ATYPICAL CARCINOID, LUNG NET, BRONCHIAL NET, CLASSIFICATION,

#3820 Metabolites in the tryptophan pathway as a diagnostic tool in neuroendocrine tumor patients

Introduction: A good and accessible biomarker is of great value in neuroendocrine tumor (NET) patients, especially considering its frequently indolent nature and long-term follow up.

Conference:

Presenting Author:

Authors: Johansen S, Hansen T, Meyer R, Jensen E, Goll R,

Keywords: serotonin, tryptophan pathway, LC-MS/MS, NEUROENDOCRINE TUMOR,

#3472 Reduction of 64Cu-DOTATATE activity dose for somatostatin receptor PET imaging of patients with neuroendocrine neoplasms

Introduction: Frequent somatostatin receptor (SSR) PET imaging is key in the clinical management of patients with neuroendocrine neoplasms (NEN) and measures to reduce the radiation exposure should be pursued.

Conference:

Presenting Author:

Authors: Loft M, Carlsen E, Johnbeck C, Jensen C, Andersen F,

Keywords: 64Cu-DOTATATE, neuroendocrine neoplasm, PET imaging, SSR imaging,

#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors

Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,

Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,

#601 Chromogranin A is a Sensitive Marker of Progression or Regression

Introduction: One of the most common is gastroenteropancreatic (GEP) NET of the pancreas, which constitute about 30% of all GEP NET. CgA is an excellent marker for NET and tumor volume and plasma CgA is suggested as the most reliable marker in follow-up of GEP but only few studies have been published.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Jensen K

Authors: Jensen K, Hilsted L, Andersen J, Mynster T, Rehfeld J,

Keywords: Chromogranin A, pancreatic neuroendocrine tumors, neuroendocrine tumors, computered tomography, RECIST 1.1, radioimmunoassay,